ESMO 2026 lung cancer trials reshape first-line care with tarlatamab maintenance, stronger KRAS G12C results, and TROP2 ADC gains, raising pharmacy monitoring demands.
Publication|Articles|June 19, 2026
Pharmacy Practice in Focus: Oncology
- June 2026
- Volume 8
- Issue 4
Evaluating Clinical Safety of BTK Inhibitors: Cardiovascular Events and Drug-Drug Interactions
Fact checked by: Kirsty Mackay
This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.
Advertisement
Advertisement
Bruton tyrosine kinase inhibitors (BTKis) are standard therapies for B-cell malignancies, including relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This study focuses on CLL/SLL. Although second-generation BTKis offer increased selectivity, their cardiovascular (CV) safety and potential drug-drug interactions (DDIs) remain incompletely characterized. This study describes CV toxicity and cytochrome P450 3A4 (CYP3A4)–mediated interactions of covalent (cBTKi) and noncovalent BTKi (ncBTKi) to inform safer therapy selection.
Related to this article
ESMO 2026 breast cancer updates show ribociclib boosts survival, while immunotherapy and extended endocrine therapy improve end points without longer overall survival.
Every-12-week immune checkpoint inhibitor dosing failed to establish noninferiority in the phase 3 MOIO trial, with an overall survival imbalance and no meaningful safety advantage over standard treatment.
Six-year NATALEE data show adjuvant ribociclib (Kisqali) plus endocrine therapy improves overall survival in high-risk HR+/HER2- early breast cancer, with pharmacist-led monitoring.
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
Before lung cancer therapy begins, diagnostic findings and treatment readiness shape care, creating opportunities for pharmacists to help patients start safely.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.
Advertisement
Advertisement